Second Generation GcMAF

Saisei Mirai’s “Second Generation GcMAF” is not GcMAF. It is serum, ie, blood with just the red blood cells centrifuged out.

They’ve only carried out one of the 22 steps it takes to make GcMAF.

Their website initially looked like a copy and paraphrase of ours, with the same picture on it we had two years earlier, so we wish to state we have no connection whatsoever with Saisei-Mirai in Japan or their “Second Generation” GcMAF.

In our opinion their “second generation” phrase is a clever sales ploy, but misleading. Our bodies have been making the same GcMAF for some thousands of years, and there is no “Second Generation” in GcMAF.

A participant asked us to test this Saisei-Mirai substance, because on its arrival it was yellow in appearance. This was unexpected, as the GcMAF produced by ourselves and by the research scientists for 20 years now, is a clear colourless liquid.

The participant was initially led to believe the “Second generation” would cost about €70 for 6 x 0.5ml vials, but actually paid an invoice for over €700 euros.

He was also led to believe by their published document “GcMAF: our next generation immunotherapy” that their definition of “Second Generation GcMAF” was that the diseased patient’s own blood was used to make it.

But no blood was asked of him; the yellow coloured substance simply arrived.

So by the Japanese company’s own definition, it seems their “Second Generation” GcMAF is not second generation.

We find this paper very odd: diseased blood is unable to make GcMAF, as any nagalase enzyme has removed the essential components required to make it.

GcMAF is a highly conserved  molecule and is the same regardless of who it comes from, meaning that there is no advantage to using your own blood as the starting point. Do they know what they are doing?

Is this the reason they state in their paper they treated only 137 people last year against our nearly 3,000?

We have a capable, well equipped laboratory.  On examination of the material using analytical techniques including Western blot, electrophoresis, SDS-PAGE, and Total Protein Quantification, the results showed very high levels of immunoglobulin IgG, which are parts of blood that we and GcMAF research scientists both ensure are excluded to make GcMAF pure and sterile.

So in our view its a half generation substance, because they’ve done much less than half the job. Electrophoresis results indicate it is mainly whole blood centrifuged (ie serum).

On their website the Japanese company appear to be unsure of the amount of GcMAF in their yellow substance, and therefore give a range. It gave us the same problem: there are too many blood constituents remaining for an exact quantity to be directly measured.

In our opinion this makes Japanese GcMAF unsuitable for people where the quantity must be accurately determined: eg autistic children, who often start on a 1ng dose, or CFS/ME, XMRV Lime disease, HIV or AIDS, where small, known doses are required to ensure dormant viruses are not made aggressive.

The Japanese company say in emails it is difficult to test their GcMAF and therefore don’t test every batch as we do.  We agree: the presence of other substances make all tests much more difficult, and testing GcMAF is a time consuming, highly specialised and expensive process. 

The definition of GcMAF has been laid out by Dr Yamamoto, scores of other scientists who have made it, and the two production companies that properly tested it.

GcMAF is the result of a 22 step production process and ends up as a clear liquid which is properly activity assayed.

In our opinion Saisei Mirai “GcMAF” does not meet these criteria, and does not meet the definition for GcMAF. All healthy serum should contain some GcMAF. The proper name for their product is therefore Serum.

Of the seven companies who have purported to manufacture GcMAF, only two have ever published internal and independent live cell assay tests.

The only way to test that GcMAF is active is with live macrophage and live cancer cell lines.  In the laboratory tests we do on GcMAF batches, we photograph through microscopes as newly activated macrophages eat cancer cells, and in the absence of macrophages, GcMAF turns the cancer cells back into healthy cells. That is how we know a batch is active.

Without those live cell tests, you are paying for an unproven substance.  In one company’s case their “GcMAF” exhibited the properties of cheap liquid vitamin D. One product was causing infections around the injection site, clear evidence it is not sterile and contains bacteria. Another company, who had been selling “GcMAF” at €1000 a shot, unusually closed down when their customers, who wasted tens of thousands of euros each, showed that it was inactive.

It goes without saying that if there are no internal, and external independent live cell tests, that product is probably inactive and should be avoided.